Janssen, the pharmaceutical division of Johnson & Johnson, today launched Invokana, a new diabetes treatment medication in India.
Taken orally once a day, Invokana belongs to a new class of medications which work in a completely different way to other classes of type 2 diabetes medications.
Type 2 diabetes is a serious chronic disease that causes glucose levels in the blood to become too high.
"The launch of Invokana in India is an exciting milestone for Janssen," Janssen India Managing Director Sanjiv Navangul said in a statement.
With the relentless increase in the number of people with type 2 diabetes in the country, there is an ongoing need for additional treatment options, he added.
Janssen has presence across various therapeutic segments including oncology and dermatology in India.
